Achieve’s cytisinicline CRL cited a prior facility and incomplete labeling, not clinical failure. Why this CMC rejection ...
Viridian’s Lumvoa approval breaks Tepezza’s TED monopoly. Inside the label, Phase 3 data, safety risks, payer hurdles and ...
Unicycive OLC received a second FDA CRL over third-party manufacturing deficiencies. The case shows why CMC risk now drives ...
AlzeCure did not prove ACD856 works in Alzheimer’s patients. It proved something else: early clinical safety, brain exposure, and a novel CNS mechanism can still be valuable enough to move a small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results